[Dr. Stéphane Leduc and the first treatments of cancer by irradiation in Nantes and France]. / Le docteur Stéphane Leduc et les premières guérisons de cancer par radiothérapie à Nantes et en France.

In August 1883, a Chair of physics was created in Nantes with Dr. Leduc (1853-1939) as the first teacher. Physician and biophysicist, he was a pioneer and visionary in many areas, including the "synthetic biology". Dr. Leduc immediately understood the importance of the discovery of the X-ray by Röntgen in 1896 for medicine. As early as in 1905, he successfully treated cancers with irradiation. In 1935, he was awarded a gold key by the American Congress of Physical Therapy for his accomplishments. The teachings of Dr Leduc largely influenced his student and successor, Dr René Gauducheau's (1881-1968) orientation towards physical and radiological sciences. This latter introduced radium therapy, and began his endeavor for the creation of a cancer center which opened its doors in 1924, recently becoming the Institut de Cancérologie de l'Ouest in 2011.

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas.

Carcinoma cells lack syndecan-1 expression when they are transiting from an epithelial to a less-differentiated mesenchymal phenotype (epithelial-mesenchymal transition, EMT). Furthermore, a shift of syndecan-1 expression from malignant epithelial cells to reactive stromal cells has also been observed during progression of many carcinomas. Finally, epithelial and/or stromal syndecan-1 expression is of prognostic value in many carcinomas. Because recent results are contradictory in breast carcinomas, we have re-evaluated the prognostic significance of syndecan-1 expression in a cohort of 80 patients with invasive ductal breast carcinomas. The tumours from 80 patients diagnosed with invasive ductal breast carcinomas were used to construct a tissue microarray, which was stained with syndecan-1 by immunohistochemistry. We correlated syndecan-1 expression with clinicopathologic parameters and relapse-free survival (RFS). Exclusive epithelial expression of syndecan-1 is observed in 61.25% of the patients, whereas exclusive stromal expression is observed in 30% of the patients. Only 8.75% of the patients had both stromal and epithelial expressions of syndecan-1. A significant correlation was found between the loss of syndecan-1 epithelial expression and the syndecan-1 stromal expression with high grade of malignancy (P=0.011). The loss of syndecan-1 epithelial expression is correlated with RFS (P=0.001). Using multivariate Cox analysis, loss of epithelial syndecan-1 expression was the only prognostic indicator (P<0.001). We concluded that the loss of syndecan-1 epithelial expression was of strong prognostic value in breast carcinomas.